Validation Data Presented by Natera Demonstrates Best-in-Class Specificity and Sensitivity of Non-Invasive Prenatal Test Panorama at Society for Maternal-Fetal Medicine Annual Meeting
2/14/2013 9:38:06 AM
SAN CARLOS, Calif.--(BUSINESS WIRE)--Natera today announced the presentation of validation data demonstrating unmatched specificity and sensitivity of the company’s non-invasive prenatal test, Panorama™. The presentation, titled “Use of targeted sequencing of SNPs to achieve a highly accurate non-invasive detection of fetal aneuploidy of 13, 18, 21, and sex chromosomes,” is being delivered at the annual meeting of the Society for Maternal-Fetal Medicine in San Francisco. The data presented is from a clinical trial evaluating Panorama’s efficacy in detecting chromosomal abnormalities from fetal cell-free DNA found in maternal blood as early as nine weeks gestation. In 764 maternal blood samples, Panorama demonstrated a sensitivity of greater than 99% when detecting common chromosomal abnormalities such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and 92% when detecting monosomy X (Turner’s syndrome). In addition, Panorama demonstrated a specificity of 100% with no false positives for all the syndromes tested.
comments powered by